The North America Hemodynamic Monitoring Devices Market would witness market growth of 4.8% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 1036.6 thousand units, showcasing a growth of 6.5% (2019-2022).
Hemodynamic monitoring systems' advantages are becoming more widely known among healthcare professionals, and an increase in educational initiatives, training programs, and strategic partnerships between major market players and healthcare organizations, research centers, and technology firms supports market growth. Moreover, it is possible to distinguish between the relative severity of pulmonary and cardiovascular dysfunction contributing to hypoxemia using hemodynamic monitoring and oxygen transport assessment. This is crucial because treatment intended to improve pulmonary dysfunction (by increasing airway pressure) may negatively affect cardiac output and venous return.
Understanding the physiological changes during the transition to newborn life is crucial for adequately interpreting any hemodynamic problems that may arise during and after this phase. It is difficult for neonatologists to treat circulatory failure during the transition; problems can vary between extremely preterm newborns and infants because premature infants have undeveloped circulations, but term infants' circulatory systems can be defective. Therefore, as the circulation changes, the strategy should be used for certain pathophysiological diseases such as patent ductus arteriosus (PDA), hypotension, intraventricular hemorrhage, newborn hypoxia, severe growth restriction, and pulmonary hypertension.
In the US, millions of people suffer from respiratory illnesses. The number of Americans having asthma is more than 25 million, according to the US Department of Health and Human Services. Asthma hospitalizations can be avoided by reducing environmental triggers and ensuring patients receive the appropriate medications. By 2040, the senior population is expected to increase, accounting for over one-fourth of everyone. In 2019, there were over 10,000 centenarians, with 82% of those who were 100 or older being female. As a result, the adoption of hemodynamic monitoring devices is expected to increase in the region, which will aid in the expansion of the market.
The US market dominated the North America Hemodynamic Monitoring Devices Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $550.3 Million by 2030. The Canada market is poised to grow at a CAGR of 7.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.2% during (2023 - 2030).
Based on Product, the market is segmented into Monitors and Disposables. Based on System Type, the market is segmented into Non-Invasive, Minimally Invasive and Invasive. Based on End Use, the market is segmented into Hospitals, Catheterization Labs, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, GE HealthCare Technologies, Inc., Baxter International, Inc., ICU Medical, Inc., Masimo Corporation, Deltex Medical Group Plc., Sramek BioDynamics, Inc., Osypka Medical GmbH, Medtronic PLC, and Koninklijke Philips N.V.
Hemodynamic monitoring systems' advantages are becoming more widely known among healthcare professionals, and an increase in educational initiatives, training programs, and strategic partnerships between major market players and healthcare organizations, research centers, and technology firms supports market growth. Moreover, it is possible to distinguish between the relative severity of pulmonary and cardiovascular dysfunction contributing to hypoxemia using hemodynamic monitoring and oxygen transport assessment. This is crucial because treatment intended to improve pulmonary dysfunction (by increasing airway pressure) may negatively affect cardiac output and venous return.
Understanding the physiological changes during the transition to newborn life is crucial for adequately interpreting any hemodynamic problems that may arise during and after this phase. It is difficult for neonatologists to treat circulatory failure during the transition; problems can vary between extremely preterm newborns and infants because premature infants have undeveloped circulations, but term infants' circulatory systems can be defective. Therefore, as the circulation changes, the strategy should be used for certain pathophysiological diseases such as patent ductus arteriosus (PDA), hypotension, intraventricular hemorrhage, newborn hypoxia, severe growth restriction, and pulmonary hypertension.
In the US, millions of people suffer from respiratory illnesses. The number of Americans having asthma is more than 25 million, according to the US Department of Health and Human Services. Asthma hospitalizations can be avoided by reducing environmental triggers and ensuring patients receive the appropriate medications. By 2040, the senior population is expected to increase, accounting for over one-fourth of everyone. In 2019, there were over 10,000 centenarians, with 82% of those who were 100 or older being female. As a result, the adoption of hemodynamic monitoring devices is expected to increase in the region, which will aid in the expansion of the market.
The US market dominated the North America Hemodynamic Monitoring Devices Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $550.3 Million by 2030. The Canada market is poised to grow at a CAGR of 7.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.2% during (2023 - 2030).
Based on Product, the market is segmented into Monitors and Disposables. Based on System Type, the market is segmented into Non-Invasive, Minimally Invasive and Invasive. Based on End Use, the market is segmented into Hospitals, Catheterization Labs, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, GE HealthCare Technologies, Inc., Baxter International, Inc., ICU Medical, Inc., Masimo Corporation, Deltex Medical Group Plc., Sramek BioDynamics, Inc., Osypka Medical GmbH, Medtronic PLC, and Koninklijke Philips N.V.
Scope of the Study
Market Segments Covered in the Report:
By Product (Volume, Thousand Units, USD Million, 2019-2030)- Monitors
- Disposables
- Non-Invasive
- Minimally Invasive
- Invasive
- Hospitals
- Catheterization Labs
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Edwards Lifesciences Corporation
- GE HealthCare Technologies, Inc.
- Baxter International, Inc.
- ICU Medical, Inc.
- Masimo Corporation
- Deltex Medical Group Plc.
- Sramek BioDynamics, Inc.
- Osypka Medical GmbH
- Medtronic PLC
- Koninklijke Philips N.V.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Hemodynamic Monitoring Devices Market by Product
Chapter 6. North America Hemodynamic Monitoring Devices Market by System Type
Chapter 7. North America Hemodynamic Monitoring Devices Market by End-use
Chapter 8. North America Hemodynamic Monitoring Devices Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Edwards Lifesciences Corporation
- GE HealthCare Technologies, Inc.
- Baxter International, Inc.
- ICU Medical, Inc.
- Masimo Corporation
- Deltex Medical Group Plc.
- Sramek BioDynamics, Inc.
- Osypka Medical GmbH
- Medtronic PLC
- Koninklijke Philips N.V.
Methodology
LOADING...
